Category: GI DynamicsSyndicate content

Study: GI Dynamics' Endobarrier comparable to gastric bypass

May 21, 2015 by Fink Densford

GI Dynamics says a head-to-head comparison of its Endobarrier weight loss device with standard gastric bypass surgery in Type II diabetics shows similar improvements to glucose metabolism.

GI Dynamics Endobarrier comparable to gastric bypass

ViewRay tables $52m IPO | Medtech Wall Street news for the week of April 13, 2015

April 16, 2015 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Report: ViewRay tables $52m IPO; GI Dynamics exercises 1-for-10 reverse split; BSD Medical rebrands as Perseon, wins expanded FDA nod for MicroThermX; Positron conducts 1-for-400 reverse stock split

Report: ViewRay tables $52m IPO

April 9, 2015 by Brad Perriello

ViewRay tables $52m IPO

GI Dynamics exercises 1-for-10 reverse split

April 13, 2015 by Val Kennedy

GI Dynamics has conducted a 1-for-10 reverse stock split in an effort to boost its lagging stock price.

GI Dynamics exercises 1-for-10 reverse split

GI Dynamics (ASX:GID) said it conducted a 1-for-10 reverse stock split in an effort to boost its flagging share price.

Valeritas sets terms for $75m IPO | Medtech Wall Street news for the week of March 9, 2015

March 12, 2015 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Diabetes: Valeritas sets terms for $75m IPO; New Siemens healthcare unit to start in May; Australia halts trading in GI Dynamics shares; Bayer aims to boost drugs sales, margins over next 3 years

Diabetes: Valeritas sets terms for $75m IPO

March 10, 2015 by Brad Perriello

Diabetes: Valeritas sets terms for $75m IPO

Olympus sold 'superbug' scopes without FDA clearance | Regulatory news for the week of March 9, 2015

March 10, 2015 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Olympus sold 'superbug' scopes without our clearance; FDA clears 1 Hospira plant, flags another; GI Dynamics plunges 50% after FDA halts trial; Sunshine Heart stops trial enrollment after patient deaths; Petition accuses Bayer's Conceptus of altering Essure trial data

FDA: Olympus sold 'superbug' scopes without our clearance

March 5, 2015 by Brad Perriello

GI Dynamics plunges 50% after FDA halts trial

March 6, 2015 by Brad Perriello

Shares of GI Dynamics lose 50% of their value after the company reveals that the FDA halted enrollment a clinical trial of its EndoBarrier weight loss device.

GI Dynamics plunges 50% after FDA halts trial

Australia halts trading in GI Dynamics shares

March 5, 2015 by Brad Perriello

GI Dynamics asks the Australian Stock Exchange to halt trading in shares of its stock pending an announcement from the weight loss device maker.

Australia halts trading in GI Dynamics shares

The Australian stock exchange today granted a request from GI Dynamics (ASX:GID) to halt trading in shares of its stock, pending a company announcement between now and March 9.